Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway

In conclusion, vorinostat reverses epithelial-mesenchymal transition by targeting UBE2C and controls the proliferation of cervical cancer cells through the ubiquitination pathway. UBE2C can be used as a promising target for the development of vorinostat treatment strategies.PMID:34331954 | DOI:10.1016/j.ejphar.2021.174399

Source: European Journal of Pharmacology - July 31, 2021 Category: Drugs & Pharmacology Authors: Botao Pan Shuanghong Yin Fang Peng Chang Liu Huiyi Liang Jiyan Su W L Wendy Hsiao Yantao Cai Dixian Luo Chenglai Xia Source Type: research